Industry
Biotechnology
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 12:26 pm
Portfolio Pulse from Benzinga Insights
May 02, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
May 01, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 15, 2024 | 10:08 am
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 11:35 am
Portfolio Pulse from Benzinga Insights
April 05, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
March 25, 2024 | 12:41 pm
Portfolio Pulse from Benzinga Insights
March 13, 2024 | 1:40 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 11:39 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.